Shopping Cart
- Remove All
- Your shopping cart is currently empty
CGP 25454A is a novel and selective antagonist of the presynaptic dopamine autoreceptor (CGP 25454A).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $134 | 5 days | |
5 mg | $228 | 5 days | |
25 mg | $613 | 6-8 weeks | |
50 mg | $797 | 6-8 weeks | |
100 mg | $1,360 | 6-8 weeks |
Description | CGP 25454A is a novel and selective antagonist of the presynaptic dopamine autoreceptor (CGP 25454A). |
In vitro | CGP 25454A increases the field-stimulated [3H]- and [14C]-overflow from rat striatal slices preloaded with [3H]dopamine and [14C]choline, indicating that CGP 25454A is able to enhance the release of both dopamine (DA) and acetylcholine (ACh). However, CGP 25454A is 12.9 times more potent in increasing, by 1/6 of the apparent maximal increase, the release of [3H]DA than that of [14C]ACh. |
In vivo | CGP 25454A increase [3H]spiperone binding to receptors of the D2 family in rat striatum by 90-110% (ED50: 13 mg/kg i.p.). At 30-100 mg/kg, CGP 25454A inhibits [3H]spiperone binding in the pituitary of the same animals as a result of a blockade of postsynaptic DA receptors. |
Molecular Weight | 346.25 |
Formula | C15H21Cl2N3O2 |
Cas No. | 104391-26-6 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 3.5 mg/mL (10.11 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.